

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/756,906	01/14/2004	Chris Andre Du Plessis	10908/8 (MAJR)	3086
757 75	90 05/01/2006		EXAMINER	
BRINKS HOFER GILSON & LIONE			WYSZOMIERSKI, GEORGE P	
P.O. BOX 10395 CHICAGO, IL 60610			ART UNIT	PAPER NUMBER
			1742	
			DATE MAILED: 05/01/2000	5

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		10/756,906	DU PLESSIS, CHRIS ANDRE
	Office Action Summary	Examiner	Art Unit
		George P. Wyszomierski	1742
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the	correspondence address
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.15 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONI	N. imely filed not the mailing date of this communication. ED (35 U.S.C. § 133).
Status			
2a)	Responsive to communication(s) filed on <u>16 Fe</u> This action is <b>FINAL</b> . 2b) This Since this application is in condition for allower	action is non-final.	rosecution as to the merits is
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.
Dispositi	on of Claims		
5)□ 6)⊠ 7)□	Claim(s) <u>1-8 and 13-19</u> is/are pending in the appearance of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) <u>1-8 and 13-19</u> is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	vn from consideration.	
Applicati	on Papers		
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ot	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).
Priority u	ınder 35 U.S.C. § 119		
12)⊠ a)[	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prior application from the International Bureau See the attached detailed Office action for a list of the certified copies.	s have been received. s have been received in Applicat ity documents have been receiv I (PCT Rule 17.2(a)).	tion No red in this National Stage
2) D Notic 3) D Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal I 6)  Other:	

Application/Control Number: 10/756,906

Art Unit: 1742

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Page 2

2. Claims 1, 2, 17 and 18 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 46-51 of copending Application No. 10/444,541. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the '541 claims and the instant claims are directed to a process which involves using micro-organisms to produce a metal-containing slurry, and separating the micro-organisms from the remainder of the slurry. While the '541 claims do not recite the term "solid/liquid separation", it would appear that conducting the '541 process under standard conditions would in fact involve a solid-liquid separation process, i.e. both a solid and liquid phase would be present and thus the step of "separating and recovering at least one bioleaching agent" in '541 claim 46 would include a step as defined in the instant claims.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422

F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. In a response filed February 16, 2006, Applicant alleges that the claimed invention can be distinguished from the previously cited Emmett et al. and Harrison references. The examiner agrees that the claimed process differs from the Emmett and Harrison references in that the prior art does <u>not</u> form a supernatant that includes microbial cells, and therefore cannot disclose separating or extracting these cells from a supernatant. As pointed out by Applicant, the process of the Emmett patents runs contrary to that claimed, i.e. in Emmett

"Whatever bacteria leave the bioreactor thus leave only in combination with product, i.e. reacted, suspended solids, to which they are physically attached. Mechanisms for the removal of soluble constituents and liquors are designed so as to not remove bacteria coincidentally." (Emmett '608 column 6, lines 41-46)

The other Emmett patents contain substantially identical disclosure, and Harrison similarly indicates that the bacteria in the Harrison process are associated with the solid phase, i.e. not with the supernatant.

Application/Control Number: 10/756,906 Page 4

Art Unit: 1742

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to George Wyszomierski whose telephone number is (571) 272-1252. The examiner can normally be reached on Monday thru Friday from 8:00 a.m. to 4:30 p.m. Eastern time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Roy King, can be reached on (571) 272-1244. All patent application related correspondence transmitted by facsimile must be directed to the <u>new central facsimile number</u>, (571)-273-8300. This new Central FAX Number is the result of relocating the Central FAX server to the Office's Alexandria, Virginia campus.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JEGRGE WYSZOMIERSK PRIMARY EXAMINER GROUP I TOW

GPW April 28, 2006